作为潜在的抗癌药物向对抗癌症的潜在抗癌药物目标,基因组伴侣
Sonam Malik1, Pramod Kumar2, Chander Prakash Yadav2
1Department of Biotechnology, Delhi Institute of Pharmaceutical Sciences and Research, New Delhi, India.
Nucleosides, nucleotides & nucleic acids
|March 10, 2025
概括
向激素陪伴剂提供了针对癌症耐药性的新策略. RBBP4被确定为开发新型表观遗传药物以提高癌症治疗疗效的关键治疗标.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子生物学分子生物学
背景情况:
- 表观遗传修饰对于癌症的发展和耐药性至关重要.
- 由于补偿机制,基因组辅导体与癌症有关.
- 向表观遗传调节剂 (表观药物) 是一个有前途的治疗策略.
研究的目的:
- 为了在基因素陪伴者中识别潜在的抗药物标.
- 分析基因伴奏子相互作用及其在癌症中的作用.
- 为了找到克服癌症药物耐药性的新治疗干预措施.
主要方法:
- 丰富和网络分析的基因素辅导体相互作用.
- 在基因伴网络中识别关键枢纽蛋白.
- 已识别的蛋白质标的药物可用性预测.
主要成果:
- 网络分析揭示了HSP90AB1,RBBP4,NPM1,DAXX和SET作为关键的基因素辅导中心蛋白质.
- 由于它与瘤发生有关,并形成最大的蛋白质,RBBP4成为了首选候选者.
- 药用性评估表明RBBP4是最有前途的目标,而Ritonavir是潜在的流行药物.
结论:
- 基因组辅助子,特别是RBBP4,是新型癌症流行药的有希望的目标.
- 了解基因组伴侣网络为开发有效的癌症疗法提供了基础.
- 准RBBP4可以提供一种新的方法来克服癌症药物耐药性.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Histone Variants at the Centromere
4.3K
Histone variants are the histone proteins with structural and sequence variations. These variants may be regarded as “mutant” forms that replace their canonical histone counterparts in the nucleosomes. Specific post-translational modifications on the histone variants enable further chromatin complexity and regulate tissue-specific gene expression. The most common histone variants are from histone H2A, H2B, and linker histone H1 families. However, several variants of histone H3...
4.3K
DNA Helicases
21.1K
DNA unwinding helicase enzymes are a type of motor protein. Motor proteins can translocate along filaments or polymers using energy generated from ATP hydrolysis. Helicases are involved in all the important cellular processes where DNA unwinding is required, such as DNA replication, repair, recombination, and transcription. They are present in all living organisms, but vary in their structure, function, and mechanism of action. For example, in prokaryotes, DnaB helicase binds and translocates...
21.1K
Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K


